Dual Costimulation Blockade May Eliminate Daily Oral Immunosuppression in Kidney Transplant скачать в хорошем качестве

Dual Costimulation Blockade May Eliminate Daily Oral Immunosuppression in Kidney Transplant

A pilot trial evaluating dual costimulatory blockade, dazodalibep + belatecept, may promote immunosuppression adherence and present a non-calcineurin treatment option for kidney transplant recipients. The phase 2a pilot trial is the first clinical trial to evaluate dual costimulation blockade in humans, with study investigators reporting that a significant number of patients did not require any daily oral medications for 1 year. “That's never been done,” said Allan Kirk, MD, PhD, a transplant surgeon at Duke Kidney/Transplant Clinic, in an interview with HCPLive. “All immunosuppressive regimens have involved at least some oral medication every single day. And this just showed proof of concept that you could do episodic therapy instead of daily therapy. And I think for patients that's a big plus.”